You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Dovato (Tivicay/Lamivudine) is now available in Ireland for the treatment of HIV-1 in adults and adolescents above 12 years of age weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine. 3

DTG

For further information on any of these products see the links to the Summary of Product Characteristics available at the top of this page.

References:

  1. Cahn P et al. J Acquir Immunde Defic Syndr . 2020;83(3):310-318
  2. van Wyk J;IAS;2019;1-16
  3. Dovato Summary of Characteristics. Available at www.medicines.ie. Last Accessed:April 2020.

Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at www.hpra.ie. Adverse reactions can also be reported to the HPRA by calling: (01) 6764971. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information.
Healthcare professionals are asked to report any suspected adverse reactions.

Trade marks are owned by or licensed to the ViiV Healthcare group of companies.